Nearly four months after Syros Pharmaceuticals licensed a drug from a company in Japan, it’s secured $40 million to move the drug into mid-stage trials. The funding adds to $83 million raised in the last two years, and was led…

AltheaDx Inc., a leading personalized medicine company, today announced it has raised $30 million in Series C financing led by WuXi Healthcare Ventures. Among the firms joining WXHV are new investors WuXi PharmaTech, Ally Bridge Group and ALMA Life Sciences.…